Generali Asset Management SPA SGR Lowers Stock Position in Hologic, Inc. $HOLX

Key Points

• Generali Asset Management SPA SGR reduced its stake in Hologic, Inc. by 63.1% in the second quarter, selling 39,367 shares and retaining 23,035 shares valued at approximately $1.5 million.
• CEO Stephen P. Macmillan sold 138,358 shares of Hologic for about $9.27 million, resulting in a 10.08% decrease in his ownership of the company's stock.
• Wall Street analysts are generally optimistic about Hologic, with a consensus rating of "Moderate Buy" and a price target average of $80.15.

Generali Asset Management SPA SGR lowered its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 63.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,035 shares of the medical equipment provider's stock after selling 39,367 shares during the period. Generali Asset Management SPA SGR's holdings in Hologic were worth $1,501,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. TD Asset Management Inc raised its holdings in shares of Hologic by 1.4% in the second quarter. TD Asset Management Inc now owns 1,530,317 shares of the medical equipment provider's stock valued at $99,715,000 after purchasing an additional 21,005 shares during the last quarter. Morningstar Investment Management LLC bought a new position in Hologic during the second quarter valued at about $357,000. Sequoia Financial Advisors LLC grew its position in Hologic by 80.6% during the second quarter. Sequoia Financial Advisors LLC now owns 11,342 shares of the medical equipment provider's stock valued at $739,000 after buying an additional 5,063 shares during the period. Yousif Capital Management LLC grew its position in Hologic by 2.1% during the second quarter. Yousif Capital Management LLC now owns 49,095 shares of the medical equipment provider's stock valued at $3,199,000 after buying an additional 1,029 shares during the period. Finally, MGO One Seven LLC grew its position in Hologic by 8.1% during the second quarter. MGO One Seven LLC now owns 3,730 shares of the medical equipment provider's stock valued at $243,000 after buying an additional 278 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares of the company's stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 1.88% of the company's stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research reports. Argus increased their price target on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research report on Friday, September 19th. Weiss Ratings restated a "hold (c-)" rating on shares of Hologic in a research report on Wednesday, October 8th. Morgan Stanley increased their price target on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research report on Thursday, July 31st. Evercore ISI set a $78.00 target price on shares of Hologic and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Finally, Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and increased their target price for the stock from $60.00 to $80.00 in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $80.15.

Hologic Price Performance

Shares of NASDAQ:HOLX opened at $69.85 on Friday. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $15.54 billion, a PE ratio of 28.98, a P/E/G ratio of 2.35 and a beta of 0.63. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.39. The company has a 50-day moving average price of $67.11 and a two-hundred day moving average price of $63.51.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the prior year, the firm posted $1.06 earnings per share. The company's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Equities analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.